Otto Jesus Hernandez Fustes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Otto Jesus Hernandez Fustes has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Paulo José Lorenzoni
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
26 shared publications - Renata Dal-Prá Ducci
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
26 shared publications - Rosana Herminia Scola
Universidade Federal do Paraná, Curitiba PR, Brazil
26 shared publications - Cláudia Suemi Kamoi Kay
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
25 shared publications - Lineu Cesar Werneck
Universidade Federal do Paraná
19 shared publications Carlos Arteaga Rodriguez
Positivo Univ, Med Dept, Curitiba, Brazil
11 shared publications
Latest Publications
- 16 November 2026
- Published by Wiley in Movement Disorders
Historical Perspectives on Spinocerebellar Ataxia Type 2: The Cuban Contribution
Spinocerebellar ataxia type 2 (SCA2) is one of the most extensively investigated hereditary ataxias worldwide. Although the first clinical description of the disorder was reported in India in 1971 by Wadia and Swami, the province of Holguín, Cuba subsequently became recognized as a major geographical focus of SCA2, with a particularly high concentration of affected families and individuals, where it became internationally recognized as Cuban ataxia. Since the late 1970s, Cuban investigators have played a pivotal role in the clinical, epidemiological, neuropathological, and genetic characterization of the disorder. This article presents a historical review of the scientific development of Cuban ataxia based on a comprehensive bibliographic and documentary analysis, complemented by interviews with key neurologists involved in its early investigation. Particular emphasis is placed on the pioneering contributions of José Rafael Estrada González, Lionel Valles Calaña, Guillermo Orozco Díaz, and Luis Velázquez Pérez, whose work established the foundations for the current understanding of SCA2. Their investigations culminated in the identification of one of the world's largest SCA2 clusters and substantially advanced knowledge of the disease's clinical spectrum, epidemiology, and molecular genetics. The Cuban experience illustrates how sustained clinical observation, multidisciplinary collaboration, and international partnerships transformed a regional neurological disorder into one of the best‐characterized hereditary ataxias worldwide. © 2026 International Parkinson and Movement Disorder Society.
- 16 November 2026
- Published by Wiley in Movement Disorders
Historical Perspectives on Spinocerebellar Ataxia Type 2: The Cuban Contribution
Spinocerebellar ataxia type 2 (SCA2) is one of the most extensively investigated hereditary ataxias worldwide. Although the first clinical description of the disorder was reported in India in 1971 by Wadia and Swami, the province of Holguín, Cuba subsequently became recognized as a major geographical focus of SCA2, with a particularly high concentration of affected families and individuals, where it became internationally recognized as Cuban ataxia. Since the late 1970s, Cuban investigators have played a pivotal role in the clinical, epidemiological, neuropathological, and genetic characterization of the disorder. This article presents a historical review of the scientific development of Cuban ataxia based on a comprehensive bibliographic and documentary analysis, complemented by interviews with key neurologists involved in its early investigation. Particular emphasis is placed on the pioneering contributions of José Rafael Estrada González, Lionel Valles Calaña, Guillermo Orozco Díaz, and Luis Velázquez Pérez, whose work established the foundations for the current understanding of SCA2. Their investigations culminated in the identification of one of the world's largest SCA2 clusters and substantially advanced knowledge of the disease's clinical spectrum, epidemiology, and molecular genetics. The Cuban experience illustrates how sustained clinical observation, multidisciplinary collaboration, and international partnerships transformed a regional neurological disorder into one of the best‐characterized hereditary ataxias worldwide. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 7 September 2026
- Published by Elsevier in eNeurologicalSci
- Vol. 45
Comment: Painful tic convulsif: Dual neurovascular compression within the spectrum of cranial nerve hyperactive dysfunction syndromes
- 7 September 2026
- Published by Elsevier in eNeurologicalSci
- Vol. 45
Open AccessComment: Painful tic convulsif: Dual neurovascular compression within the spectrum of cranial nerve hyperactive dysfunction syndromes
- 3 September 2026
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 20 (5) , 126
Thalamic dysconnection and sensorimotor impairment in SCA10
- 3 September 2026
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 20 (5) , 126
Thalamic dysconnection and sensorimotor impairment in SCA10
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-004
Amyotrophic lateral sclerosis (ALS): new insights 156 years after Charcot's masterful description
In 1869, Charcot and Alix Joffroy published the first detailed clinical and neuropathological description of amyotrophic lateral sclerosis (ALS), establishing the correlation involving muscle weakness, atrophy, spasticity, and degeneration of the lateral corticospinal tracts. Charcot unified the involvement of upper and lower motor neurons into a single clinical entity. His pioneering description was limited to the motor system, reflecting the scientific constraints of his time. Charcot interpreted ALS primarily as a disorder of the motor system, a conclusion consistent with the clinical and pathological methods available in the late nineteenth century. Neurological investigation at that time relied mainly on detailed clinical observation, anatomical correlation at autopsy, and relatively-simple physiological techniques. These approaches were well suited to identify motor dysfunction but were far less capable of revealing subtle cognitive or behavioral alterations. Currently, ALS is recognized as a multisystem neurodegenerative disorder. Thus, Charcot's historical contribution was crucial for the initial understanding of ALS, while modern perspectives acknowledge its broader clinical complexity beyond the motor system.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-004
Open AccessAmyotrophic lateral sclerosis (ALS): new insights 156 years after Charcot's masterful description
In 1869, Charcot and Alix Joffroy published the first detailed clinical and neuropathological description of amyotrophic lateral sclerosis (ALS), establishing the correlation involving muscle weakness, atrophy, spasticity, and degeneration of the lateral corticospinal tracts. Charcot unified the involvement of upper and lower motor neurons into a single clinical entity. His pioneering description was limited to the motor system, reflecting the scientific constraints of his time. Charcot interpreted ALS primarily as a disorder of the motor system, a conclusion consistent with the clinical and pathological methods available in the late nineteenth century. Neurological investigation at that time relied mainly on detailed clinical observation, anatomical correlation at autopsy, and relatively-simple physiological techniques. These approaches were well suited to identify motor dysfunction but were far less capable of revealing subtle cognitive or behavioral alterations. Currently, ALS is recognized as a multisystem neurodegenerative disorder. Thus, Charcot's historical contribution was crucial for the initial understanding of ALS, while modern perspectives acknowledge its broader clinical complexity beyond the motor system.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-007
The skin-wrinkling test: principles and clinical applications
Cutaneous wrinkling is a normal phenomenon that occurs on the palms in a reversible manner and results from vasoconstriction influenced by vasomotor function. It can be assessed through the skin-wrinkling test following water immersion, with the absence or reduction of wrinkling being associated with disorders affecting the dense network of sympathetic nerves in these regions. The literature suggests that this test may serve as a screening tool for small-fiber neuropathy, particularly in settings in which biopsy is not available. It is a rapid, inexpensive, and easily-accessible test. We herein review the principles of the skin-wrinkling test, its pathophysiology, and its clinical indications as a tool to evaluate the sympathetic component of the autonomic nervous system.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-007
Open AccessThe skin-wrinkling test: principles and clinical applications
Cutaneous wrinkling is a normal phenomenon that occurs on the palms in a reversible manner and results from vasoconstriction influenced by vasomotor function. It can be assessed through the skin-wrinkling test following water immersion, with the absence or reduction of wrinkling being associated with disorders affecting the dense network of sympathetic nerves in these regions. The literature suggests that this test may serve as a screening tool for small-fiber neuropathy, particularly in settings in which biopsy is not available. It is a rapid, inexpensive, and easily-accessible test. We herein review the principles of the skin-wrinkling test, its pathophysiology, and its clinical indications as a tool to evaluate the sympathetic component of the autonomic nervous system.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-006
Clinical profile and quality of life in late-onset and very-late-onset myasthenia gravis: a cross-sectional study
The incidence of late-onset and very-late-onset myasthenia gravis (MG) has increased worldwide, but national data in Brazil remain scarce. Characterizing the clinical profile and quality of life (QoL) of these patients is essential to improve care strategies. To describe the clinical profile and assess QoL of patients with late- and very-late-onset MG followed at a Brazilian tertiary hospital, comparing them with early-onset MG patients. Cross-sectional observational study including adult MG patients followed at a tertiary university hospital. Demographic, clinical, serological, neurophysiological, and radiological data were collected. Disease severity was assessed using the Myasthenia Gravis Composite (MGC) and Quantitative Myasthenia Gravis (QMG) scales. Furthermore, QoL was assessed using the 15-item Myasthenia Gravis QoL questionnaire (MG-QOL15). Correlation analyses were performed between MG-QOL15, MGC, and QMG scores. In total, 28 MG patients were included: 13 early-onset, 7 late-onset, and 8 very-late-onset. Male predominance, shorter disease duration, and absence of thymectomy were more frequent in the late and very-late-onset groups. These subgroups also showed better symptom control and perceived QoL, particularly the very-late-onset group. The MG-QOL15 scores showed a moderate correlation with MGC and a weaker correlation with QMG. Late-onset and very-late-onset MG patients showed satisfactory QoL and clinical profiles, consistent with international data. These correlations reinforce the complementary role of patient-reported outcomes alongside objective clinical scales. Further studies with larger cohorts and longitudinal follow-up are needed.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-006
Open AccessClinical profile and quality of life in late-onset and very-late-onset myasthenia gravis: a cross-sectional study
The incidence of late-onset and very-late-onset myasthenia gravis (MG) has increased worldwide, but national data in Brazil remain scarce. Characterizing the clinical profile and quality of life (QoL) of these patients is essential to improve care strategies. To describe the clinical profile and assess QoL of patients with late- and very-late-onset MG followed at a Brazilian tertiary hospital, comparing them with early-onset MG patients. Cross-sectional observational study including adult MG patients followed at a tertiary university hospital. Demographic, clinical, serological, neurophysiological, and radiological data were collected. Disease severity was assessed using the Myasthenia Gravis Composite (MGC) and Quantitative Myasthenia Gravis (QMG) scales. Furthermore, QoL was assessed using the 15-item Myasthenia Gravis QoL questionnaire (MG-QOL15). Correlation analyses were performed between MG-QOL15, MGC, and QMG scores. In total, 28 MG patients were included: 13 early-onset, 7 late-onset, and 8 very-late-onset. Male predominance, shorter disease duration, and absence of thymectomy were more frequent in the late and very-late-onset groups. These subgroups also showed better symptom control and perceived QoL, particularly the very-late-onset group. The MG-QOL15 scores showed a moderate correlation with MGC and a weaker correlation with QMG. Late-onset and very-late-onset MG patients showed satisfactory QoL and clinical profiles, consistent with international data. These correlations reinforce the complementary role of patient-reported outcomes alongside objective clinical scales. Further studies with larger cohorts and longitudinal follow-up are needed.
- Open Access
- 17 April 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 57
Somatosensory Evoked Potentials in Spinocerebellar Ataxia Type 3 and Type 10
Spinocerebellar ataxias (SCAs) are heterogeneous neurodegenerative disorders with variable phenotypes. Somatosensory evoked potentials (SSEPs) provide insights into the integrity of the dorsal-lemniscal pathway. This study aimed to evaluate SSEP findings in patients with SCA3 and SCA10 and compare their neurophysiological profiles. We conducted a cross-sectional study including 20 SCA3 patients and 20 SCA10 patients under follow-up at a tertiary ataxia clinic in Southern Brazil. Clinical assessment comprised demographic, genetic, and phenotypic characterization, including the Scale for the Assessment and Rating of Ataxia (SARA). SSEPs were recorded bilaterally after median and tibial nerve stimulation, assessing latencies and amplitudes of N9, N20, N21, and P40 potentials, as well as interpotential intervals. Examinations were classified as normal or abnormal, and abnormalities were categorized. Abnormal SSEPs were detected in 18 SCA3 patients (90%) and in 3 SCA10 patients (15%) ( p < 0.001). In SCA3, abnormalities predominantly involved central generators. In contrast, most SCA10 patients exhibited normal SSEPs, with only a few isolated cortical responses and interval abnormalities. No significant associations were found between SSEP abnormalities and demographic, clinical, imaging, or genetic variables in either group. SCA3 shows widespread somatosensory dysfunction, whereas SCA10 patients, particularly in Southern Brazil, show preserved SSEPs consistent with pure cerebellar ataxia. These findings highlight distinct neurophysiological signatures in SCAs, reinforcing their heterogeneity and supporting SSEPs as candidate markers for differential characterization, requiring validation.
- 17 April 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 57
Open AccessSomatosensory Evoked Potentials in Spinocerebellar Ataxia Type 3 and Type 10
Spinocerebellar ataxias (SCAs) are heterogeneous neurodegenerative disorders with variable phenotypes. Somatosensory evoked potentials (SSEPs) provide insights into the integrity of the dorsal-lemniscal pathway. This study aimed to evaluate SSEP findings in patients with SCA3 and SCA10 and compare their neurophysiological profiles. We conducted a cross-sectional study including 20 SCA3 patients and 20 SCA10 patients under follow-up at a tertiary ataxia clinic in Southern Brazil. Clinical assessment comprised demographic, genetic, and phenotypic characterization, including the Scale for the Assessment and Rating of Ataxia (SARA). SSEPs were recorded bilaterally after median and tibial nerve stimulation, assessing latencies and amplitudes of N9, N20, N21, and P40 potentials, as well as interpotential intervals. Examinations were classified as normal or abnormal, and abnormalities were categorized. Abnormal SSEPs were detected in 18 SCA3 patients (90%) and in 3 SCA10 patients (15%) ( p < 0.001). In SCA3, abnormalities predominantly involved central generators. In contrast, most SCA10 patients exhibited normal SSEPs, with only a few isolated cortical responses and interval abnormalities. No significant associations were found between SSEP abnormalities and demographic, clinical, imaging, or genetic variables in either group. SCA3 shows widespread somatosensory dysfunction, whereas SCA10 patients, particularly in Southern Brazil, show preserved SSEPs consistent with pure cerebellar ataxia. These findings highlight distinct neurophysiological signatures in SCAs, reinforcing their heterogeneity and supporting SSEPs as candidate markers for differential characterization, requiring validation.
- Open Access
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-008
Prevalence and predictors of low bone mineral density in Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease affecting the postsynaptic neuromuscular junction. Treatment often includes corticosteroids, which may reduce bone mass. To evaluate the prevalence and predictors of low bone mineral density (BMD) in MG patients. A cross-sectional study included patients over 18 years with MG followed at the Neuromuscular Diseases Service, Hospital de Clínicas, Universidade Federal do Paraná (2018–2022). Data were obtained through clinical evaluation, medical records, MG Composite Scale, and Quantitative MG Test. Lumbar spine and proximal femur BMD were assessed using a GE Lunar densitometer, with T or Z-scores according to age/menopausal status. Logistic regression identified factors independently associated with BMD alterations. In total, 92 patients (64.1% female, mean age: 51.3 years) were included, of whom 79.3% had early-onset MG. Past or present corticosteroid use were reported in 94.5 and 45.6%, respectively. Only 27.6% practiced regular physical activity, though most had adequate calcium intake. There were six (7.8%) patients with fragility fractures, and ⅕ were at high fracture risk according to the FRAX results. We found that BMD alterations occurred in 43.5% of patients. No significant association was found with corticosteroid use or MG severity. Age was independently associated with BMD (OR = 1.06, 95% CI: 1.03–1.09, p = 0.0005). A cutoff age ≥ 49 years yielded 82.5% sensitivity, 63.5% specificity, and an area under the ROC curve of 0.72 (95% CI: 0.61–0.83). Reduced BMD is frequent in MG, highlighting the importance of screening and prevention of low bone mass, osteoporosis, and fragility fractures, particularly in patients over 49 years, regardless of corticosteroid use or MG severity.
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-008
Open AccessPrevalence and predictors of low bone mineral density in Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease affecting the postsynaptic neuromuscular junction. Treatment often includes corticosteroids, which may reduce bone mass. To evaluate the prevalence and predictors of low bone mineral density (BMD) in MG patients. A cross-sectional study included patients over 18 years with MG followed at the Neuromuscular Diseases Service, Hospital de Clínicas, Universidade Federal do Paraná (2018–2022). Data were obtained through clinical evaluation, medical records, MG Composite Scale, and Quantitative MG Test. Lumbar spine and proximal femur BMD were assessed using a GE Lunar densitometer, with T or Z-scores according to age/menopausal status. Logistic regression identified factors independently associated with BMD alterations. In total, 92 patients (64.1% female, mean age: 51.3 years) were included, of whom 79.3% had early-onset MG. Past or present corticosteroid use were reported in 94.5 and 45.6%, respectively. Only 27.6% practiced regular physical activity, though most had adequate calcium intake. There were six (7.8%) patients with fragility fractures, and ⅕ were at high fracture risk according to the FRAX results. We found that BMD alterations occurred in 43.5% of patients. No significant association was found with corticosteroid use or MG severity. Age was independently associated with BMD (OR = 1.06, 95% CI: 1.03–1.09, p = 0.0005). A cutoff age ≥ 49 years yielded 82.5% sensitivity, 63.5% specificity, and an area under the ROC curve of 0.72 (95% CI: 0.61–0.83). Reduced BMD is frequent in MG, highlighting the importance of screening and prevention of low bone mass, osteoporosis, and fragility fractures, particularly in patients over 49 years, regardless of corticosteroid use or MG severity.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-6
Somatosensory evoked potentials in neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are rare antibody-mediated disorders of the central nervous system with a predilection for the spinal cord and optic nerves. Our objective is to evaluate the dorsolemniscal system using the somatosensory evoked potential, specifically the registration of the N20 and P40 waves. The Somatosensory evoked potentials (SSEP) were prospectively performed in 13 patients with NMOSD. All the patients were recruited from the outpatient clinic of a demyelinating diseases center from Southern Brazil. We evaluated 12 female with mean age of 42 years-old and one man of 25 years-old. When categorized in relation to the variable SSEP (Normal vs. Abnormal), there was a statistical difference in relation to N20, N21 and P40 latencies. SSEP showed a significant increase in N20 and P40 latencies. SSEP is a non-invasive, painless, fast and low-cost exam which provides neurophysiological data for diagnosis of NMOSD.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-6
Somatosensory evoked potentials in neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are rare antibody-mediated disorders of the central nervous system with a predilection for the spinal cord and optic nerves. Our objective is to evaluate the dorsolemniscal system using the somatosensory evoked potential, specifically the registration of the N20 and P40 waves. The Somatosensory evoked potentials (SSEP) were prospectively performed in 13 patients with NMOSD. All the patients were recruited from the outpatient clinic of a demyelinating diseases center from Southern Brazil. We evaluated 12 female with mean age of 42 years-old and one man of 25 years-old. When categorized in relation to the variable SSEP (Normal vs. Abnormal), there was a statistical difference in relation to N20, N21 and P40 latencies. SSEP showed a significant increase in N20 and P40 latencies. SSEP is a non-invasive, painless, fast and low-cost exam which provides neurophysiological data for diagnosis of NMOSD.
- Open Access
- 1 January 2026
- Published by Wiley in Neurology Research International
- Vol. 2026 (1)
Outcome and Quality of Life in Guillain–Barré Syndrome in Southern Brazil
Background: Guillain–Barré Syndrome (GBS) is an acute immune‐mediated polyradiculoneuropathy with an annual incidence of 0.4 per 100,000 inhabitants in Brazil. Clinical manifestations range from mild weakness to tetraplegia with respiratory failure. Objective: To analyze the impact on the quality of life of adult patients diagnosed with GBS in the short and medium term. Methods: This regional descriptive, cross‐sectional study included 46 hospitalized patients with confirmed GBS. Functional status was measured using the overall disability sum score (ODSS), and quality of life was evaluated with the WHOQOL‐BREF instrument. Results: During the study period, 57 patients were diagnosed with GBS; 11 met exclusion criteria, and 5 died, yielding a mortality rate of 8.7%. All deceased patients were older than 55 years (mean 59,6 p = 00, 008) and presented with respiratory failure. Higher Hughes scores at admission (mean 3.8 vs. 2.75; p = 0.039) and longer duration of antecedent symptoms (24.33 vs. 14.80 days; p = 0.036)were significantly associated with mortality. Moderate/high‐risk mEGOS scores were present in 80% of deceased patients ( p = 0.008). Quality of life perceptions improved most between 6 and 12 months postdiagnosis, while functional recovery (ODSS) was observed after 12 months. Conclusion: Higher admission neurological disability was associated with greater functional impairment in this cohort, while quality of life improved during follow‐up and functional recovery continued beyond 12 months. Higher Hughes scores and moderate‐to‐high mEGOS risk were associated with mortality in univariable analyses, but the small number of deaths and absence of multivariable adjustment preclude conclusions regarding independent prognostic effects. Extended follow‐up is important to capture the gradual trajectory of functional and psychosocial recovery in GBS.
- 1 January 2026
- Published by Wiley in Neurology Research International
- Vol. 2026 (1)
Open AccessOutcome and Quality of Life in Guillain–Barré Syndrome in Southern Brazil
Background: Guillain–Barré Syndrome (GBS) is an acute immune‐mediated polyradiculoneuropathy with an annual incidence of 0.4 per 100,000 inhabitants in Brazil. Clinical manifestations range from mild weakness to tetraplegia with respiratory failure. Objective: To analyze the impact on the quality of life of adult patients diagnosed with GBS in the short and medium term. Methods: This regional descriptive, cross‐sectional study included 46 hospitalized patients with confirmed GBS. Functional status was measured using the overall disability sum score (ODSS), and quality of life was evaluated with the WHOQOL‐BREF instrument. Results: During the study period, 57 patients were diagnosed with GBS; 11 met exclusion criteria, and 5 died, yielding a mortality rate of 8.7%. All deceased patients were older than 55 years (mean 59,6 p = 00, 008) and presented with respiratory failure. Higher Hughes scores at admission (mean 3.8 vs. 2.75; p = 0.039) and longer duration of antecedent symptoms (24.33 vs. 14.80 days; p = 0.036)were significantly associated with mortality. Moderate/high‐risk mEGOS scores were present in 80% of deceased patients ( p = 0.008). Quality of life perceptions improved most between 6 and 12 months postdiagnosis, while functional recovery (ODSS) was observed after 12 months. Conclusion: Higher admission neurological disability was associated with greater functional impairment in this cohort, while quality of life improved during follow‐up and functional recovery continued beyond 12 months. Higher Hughes scores and moderate‐to‐high mEGOS risk were associated with mortality in univariable analyses, but the small number of deaths and absence of multivariable adjustment preclude conclusions regarding independent prognostic effects. Extended follow‐up is important to capture the gradual trajectory of functional and psychosocial recovery in GBS.